Fluoptics
To market and sell its technology for preclinical in vivo fluorescence imaging, !%Fluoptics%! of Grenoble, France, a developer of image-guided surgical equipment, has opened an office in Cambridge, Mass. The company develops integrated solutions that combine a nonradioactive fluorescent tracer targeting cancer cells with its Fluobeam real-time optical imaging system. The proprietary device, due to enter clinical trials this year in Europe, is already available to the preclinical research market. More than 15 units have been sold worldwide. Once approved for the clinical market, the technology will help surgeons see what the naked eye cannot; e.g., it will illuminate cancer cells in real time for the surgeon performing the resection of cancerous tumors using natural light.
LATEST NEWS
- CLEO Heads to the East Coast
Apr 29, 2024
- Laser-Based Gas Analyzer Developed to Detect Air Pollution
Apr 29, 2024
- Qubits Could be Stored in Flash-Like Memory
Apr 29, 2024
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024